GlobeNewsWire
18 Jul 2026, 19:15 UTC · 16w ago
Verdict
Headline takes no side. We score FDMT +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b clinical trial for its 4D-150 gene therapy in wet AMD patients.
More positive than 99% of claims this week
The 4D-150 candidate is designed to replace frequent bolus injections with a single intravitreal injection providing multi-year delivery of anti-VEGF biologics.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 93% of claims this week
4D-150 has progressed into Phase 3 development for its lead indication of wet age-related macular degeneration.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced positive 2-year data from its Phase 2b clinical trial for 4D-150 in treating wet AMD.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
+18.2%
Price agrees with the score
$12.99 vs $10.99 close before publication (Jul 17) · not market-adjusted
FDMT chart →
